Skip Navigation

Pipeline

Oncology / Immuno-oncology

All Arvinas programs, with the exception of ARV-471, are wholly owned.

Program
Exploratory
Research
IND Enabling
Phase 1
Phase 2
Phase 3
Bavdegalutamide (ARV-110) mCRPC

Phase 2

Bavdegalutamide (ARV-110) is a clinical stage, oral PROTAC® degrader that targets the androgen receptor (AR), a highly validated driver of prostate cancer. More information is available here.

ARV-766 mCRPC

Phase 1

ARV-766 is an oral PROTAC® protein degrader that targets the androgen receptor (AR) and has a different profile than bavdegalutamide (ARV-110).

AR-V7 mCRPC

Exploratory

AR-V7 is a splice variant of androgen receptor (AR). Our AR-V7-targeting PROTAC® protein degrader is a next-generation AR PROTAC that would target both AR-V7 and full-length AR.

ARV-471 ER+/HER2-Breast Cancer

Phase 2

Global partners with

ARV-471 is a clinical stage, oral PROTAC® degrader that targets the estrogen receptor (ER), a highly validated driver of breast cancer. In July 2021, Arvinas and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471. More information is available here.

BCL6 B-cell Malignancies

Research

B-cell lymphoma 6 protein (BCL6) is a transcriptional repressor implicated in B cell lymphomas by facilitating B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. PROTAC®-mediated degradation would address the scaffolding function of BCL6.

KRAS G12D/V NSCLC, CRC, Pancreatic

Research

Kirsten rat sarcoma (KRAS) is a classic “undruggable” target, due to its lack of deep “pockets,” and is associated with poor prognosis and resistance to standards of care in several tumor types. Arvinas is developing pan-KRAS mutant and mutant-specific KRAS degraders, e.g., G12D and G12V.

Undisclosed Oncology Program Solid Malignancies

Research

Myc Solid Malignancies

Exploratory

Myelocytomatosis (Myc) proteins are implicated in up to 70% of all human cancers. Targeting Myc indirectly, such as by inhibiting transcription modulators, has not been successful, but PROTAC®-mediated degradation has the potential to directly target and degrade Myc.

HPK1 (I-O Program) Solid Malignancies

Exploratory

Hematopoietic progenitor kinase 1 (HPK1) is a suppressor of T cell activation and targeting HPK1 can enhance anti-tumor immune responses. PROTAC®-mediated degradation has the potential to address the proposed scaffolding component of HPK1’s activity.

Neuroscience

All Arvinas programs are wholly owned

Program
Exploratory
Research
IND Enabling
Phase 1
Phase 2
Phase 3
Tau FTLD-TAU, PSP, AD

Research

Tau is a key disease driver in many tauopathies, including Alzheimer’s disease and progressive supranuclear palsy. Our PROTAC® protein degrader targets pathogenic tau without degrading healthy forms of tau. More information is available here.

Alpha Synuclein MSA, Parkinson's

Exploratory

The pathologic aggregation of α-synuclein is a key driver in many synucleinopathies, including Parkinson’s disease. Our PROTAC® protein degraders specifically degrade oligomeric forms of α-synuclein, which forms disease-causing aggregates. More information is available here.

mHTT Huntington's

Exploratory

Huntington’s disease is caused by a mutation in the huntingtin (HTT) gene. PROTAC® degradation has the potential to allow the selective targeting of mutant HTT protein without impacting wild-type HTT protein.

Undisclosed Neuroscience Program Neurodegeneration

Exploratory